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Abstract  
 
GM-CSF promotes growth, survival, differentiation and activation of normal myeloid 
cells and plays an important role in myeloid leukemias. The GM-CSF receptor (GMR) 
shares a common signaling subunit, βc, with IL-3 and IL-5 receptors and has recently 
been shown to induce activation of JAK2 and downstream signaling pathways via 
formation of a unique dodecameric receptor complex. In this study we use two activated 
βc mutants that display distinct signaling capacity, and have a differential requirement for 
the GM-CSF receptor α-subunit (GMRα), to dissect the signaling pathways associated 
with GM-CSF response. The V449E trans-membrane mutant selectively activates 
JAK/STAT5 and MAPK pathways resulting in a high level of sensitivity to JAK and 
MEK inhibitors while the extracellular mutant (FIΔ) selectively activates the PI3K/Akt 
and IκKβ/NFκB pathways. We also demonstrate a novel and direct interaction between 
the SH3 domains of Lyn and Src with a conserved proline-rich motif in GMRα,  and  
show  a  selective requirement for Src Family Kinases (SFKs) by the FIΔ mutant. We 
relate the non-overlapping nature of signaling by these two activated mutants to the 
structure of the unique GM-CSF receptor complex and propose alternative modes of 
receptor activation, differentially dependent on JAK2 and SFK, and acting synergistically 
in the mature liganded receptor complex.   
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Introduction 
 
The GM-CSF, IL-3 and IL-5 receptors are key contributors to the regulation of normal 
hematopoiesis mediating growth and survival of haemopoietic progenitor cells and the 
production and activation of mature haemopoietic cells. GM-CSF in particular can 
provide both permissive and instructive signals for myeloid differentiation1 and has been 
shown to play a critical role in dendritic cells (DC).2 While dispensible for steady state 
hematopoiesis,3 it has an important accessory role in radioprotection by donor 
hematopoietic cells.4 It also has a non-redundant role in surfactant clearance by alveolar 
macrophages resulting in lung disease in GM-CSF null animals.5 Null animals display 
compromised antigen-specific and LPS induced T-cell responses and IFNγ production, 
have defects in macrophage function,6 and are susceptible to various infectious agents.7 
GM-CSF and IL-3 have important roles in leukemia with autocrine production and over-
expression of their ligand-binding subunits (IL-3Rα and GMRα) documented in AML.8,9 
Constitutive activation of GM-CSF survival pathways has been reported in AML10 and 
GM-CSF has also recently been shown to play an important role in primary resistance in 
CML.11 
 
GM-CSF induces activation of JAK2 and downstream signaling pathways via formation 
of a unique dodecameric receptor complex.12 Activation of JAK2/STAT5, Ras-Raf-
MAPK, and PI3K-Akt pathways by the mature GM-CSF receptor have been well 
characterised both in normal hematopoiesis and in disease where aberrant signaling has 
been shown to contribute to dysregulated myelopoiesis.13  However, extensive signaling 
redundancy and cross-talk among cytokine receptors (CRs) has made it difficult to link 
individual pathways to specific functional outcomes such as cell survival, proliferation 
and differentiation. Activation of one pathway often feeds into another resulting in a 
networked signaling response, the final outcome of which is influenced by the cell 
context, stage of differentiation, transformation and microenvironment.14 It is also clear 
that many signaling pathways converge on the same signaling molecules and some 
biological effects can be mediated by multiple effectors.  
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In part, signaling redundancy of CRs can be attributed to the sharing of receptor subunits. 
GM-CSF, IL-3 and IL-5 receptors, share the common beta subunit (βc) which is the 
primary signaling subunit that is pre-associated with JAK2 and contains several tyrosines 
which upon phosphorylation provide protein docking sites for activation of signal 
transduction. Specificity of this class of CRs is achieved through ligand-specific alpha 
subunits that enable affinity conversion of the receptor complex in the presence of a 
specific ligand.15 Although essential for receptor function, determining the precise 
signaling contribution of the α−subunits has been hampered by the lack of understanding 
of the role of interacting molecules. Deletion of the short cytoplasmic domain of the GM-
CSF receptor α subunit (GMRα) abolishes ligand-induced signaling with no effect on 
ligand binding.16  The membrane-proximal region, and in particular, the SH3 binding 
site/PROX-like (SBP) motif17 is essential for GM-CSF-induced activation of JAK2.18  
Some signaling molecules have been shown to associate with the GMRα cytoplasmic 
domain including the p85 regulatory subunit of PI3K,19 and IκKβ,20 however, the nature 
and the role of these interactions remains poorly characterised. Nevertheless, it is 
interesting to note that although GMRα is essential for GM-CSFR activation it does not 
signal by itself, an important feature that emphasises the importance of the GMRα 
interaction with βc.   
 
To reduce the level of signaling complexity and dissect the contribution of signaling 
events activated by GMR we have used two constitutively activated mutants of βc 
(V449E and FIΔ) that deliver a subset of the proliferation, survival and differentiation 
signals induced by the ligand-activated GMR and display a differential requirement for 
the GMRα.21,22 Specifically, the strict requirement of the FIΔ mutant for GMRα suggests 
a minimal heterodimeric structure26 in contrast to the V449E transmebrane mutant which 
is thought to signal as a βc homodimer, independently of GMRα.26 The differential 
activity of these two mutants is also clear in vivo, where expression of the extracellular 
mutant, FIΔ, induces a chronic myeloproliferative disorder (MPD), whereas expression of 
the V449E transmembrane mutant by mouse BM reconstitution results in an acute 
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myeloid leukemia (AML).23 To understand the differences in signaling between these two 
classes of activating mutants we have used the bi-potential murine myeloid cell line, 
FDB1, which switches between growth or granulocyte-macrophage (GM) differentiation 
in response to IL-3 or GM-CSF respectively.22,24 Expression of hβc mutants, V449E and 
FIΔ, in these cells induces factor independent proliferation or GM differentiation 
respectively, mimicking the functional response to cytokines. Here we describe non-
overlapping signaling signatures of two βc activated mutants and propose a model 
whereby each initiates a subset of the signaling activated by the mature ligand-bound 
dodecameric GMR. We report an important contribution of JAK2-independent signaling 
from the FIΔ mutant and demonstrate novel and potentially critical interactions of both 
Lyn and Src with GMRα. We propose that these interactions are critical in modulating 
signals generated by GMR and suggest an important role for accessory subunits in 
modulating signaling of other CRs.  
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Material and Methods 
 
Cell Culture and Transfections. The culture conditions of FDB1 cells, the construction 
of FIΔ and V449E retroviral expression plasmids, and the generation of stable cell lines 
were conducted as previously described.24 FIΔ and V449E receptor expression was 
maintained through the addition of puromycin to culture media, and assessed by flow 
cytometry using the anti-flag M2 antibody (Sigma-Aldrich, NSW, Australia). Prior to 
treatment of cells with inhibitors, cells were washed three times and starved of growth 
factors for 12-16h in medium containing serum. Stimulation was carried out for 5 min at 
37°C using 500U mIL-3 or mGM-CSF. Unless otherwise indicated the final 
concentration of inhibitors was 50µM PD98069; 25µM AG490, Jak2InhII, U0126, 
LY294002, PP1 and Lyn Peptide Inhibitor; 0.5µM Wortmannin; and 5µM SU6656. All 
inhibitors were purchased from Merck (Darmstadt, Germany) with the exception of the 
Lyn Peptide Inhibitor which was obtained from Tocris Bioscience (Bristol, UK). 
Transient transfections were carried out using Lipofectamine 2000 (Invitrogen, Carlsbad, 
CA). 
 
Co-Immunoprecipitation and Western Immunoblot Analysis.  Cells were lysed in 
Modified RIPA Lysis Buffer (MRLB), separated by SDS-PAGE, and transferred to 
nitrocellulose. Proteins of interest were detected using the antibodies described below and 
SuperSignal West Pico or West Dura substrates. Rabbit polyclonal anti-JAK2 
[pYpY1007/1008] was purchased from Biosource (Camarillo, CA). The mouse monoclonal 
anti-phospho-STAT5A/B (Tyr694/699), STAT3 and STAT5 antibodies were obtained 
from Upstate Cell Signaling Solutions (Lake Placid, NY).  Rabbit polyclonal Phospho-
IκBα (Ser32/36), Phospho-Akt (Ser473), Akt, Phospho-p44/42 Map Kinase 
(Thr202/Tyr204) and p44/42 Map Kinase, Phospho-Src family (Y416), Phospho-Lyn, 
Src, Lyn, and p85 antibodies were purchased from Cell Signaling Technology (Beverly, 
MA). Secondary IgG antibodies and SuperSignal West Pico and West Dura detection 
substrates were obtained from Pierce Biotechnology (Rockford, IL).  The secondary anti-
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mouse FITC conjugated antibody was purchased from Sigma Aldrich (St Louis, MO). 
For co-immunoprecipitation, lysates were incubated overnight with 5µg of 4H1 antibody 
(kind gift from Tim Hercus) or IgG1 isotype control and 50µl of protein A/G sepharose. 
The sepharose was washed with MRLB, boiled in SDS load buffer and immunoblotted.  
 
GST Pull-Downs. Glutathione-S-transferase proteins containing SH3 domains from Src 
(aa 83-150), Lyn (aa 62-122) and p85 (aa 3-79) were affinity purified on 4MB-
glutathione sepharose (Amersham). 500µg cell lysate from HEK293T cells expressing 
hGMRα or hGMRα-APVA was incubated with GST-SH3-sepharose conjugates 
overnight at 4°C. Precipitates were washed with MRLB three times and proteins were 
eluted in SDS-PAGE load buffer. 
 
Intracellular Flow Cytometry. Cells were fixed using a final concentration of 1.6% 
formaldehyde at 37°C for 15 min, permeabilised in 1ml ice cold methanol on ice for 30 
min and incubated with the 5µg/µl primary antibody (unless otherwise stated) for 30 min 
on ice. Following incubation with corresponding FITC-conjugated secondary antibodies 
on ice for 30 min, samples were analysed by flow cytometry (Beckman-Coulter Epics 
Elite ESP Flow Cytometer/Cell Sorter).  
 
Fluorescence Polarization. GST fusion proteins were prepared for mLyn, mSrc and 
mp85 SH3 domains.  A black 96-well plate was blocked with casein for 1 hour at 37°C. 
Samples were incubated in triplicate  with 100nM fluoroscein labelled mGMRα peptide 
(mGMRα-pep; fluorescien-RLFPPIPGI, mGMRα-pep) and 25µg GST-SH3. A 
mGMRα-pep only and mGMRα-pep + GST were used. The assay plate was incubated 
for 5 minutes at room temperature prior to reading on the FLUOstar OPTIMA (BMG 
Labtechnologies) fluorescence plate reader at an excitation wavelength of 520nm. Data 
was analysed using FLUOstar Galaxy software and polarisation values of the controls, 
were subtracted from the other sample values to obtain the relative change in polarisation 
(ie. ΔmP value) for the test samples. 
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Results 
 
Signaling from the GM-CSF receptor FIΔ mutant is predominantly JAK2 and ERK 
independent.  
GM-CSF signaling is primarily mediated by activation of JAK2 associated with the 
cytoplasmic domain of βc. JAK2 phosphorylation is dependent on an intact PXXP motif 
in the GMRα subunit which, when mutated, abolishes JAK2/STAT5 signaling.25 Given 
this requirement for GMRα in JAK2 signaling, we tested the activation and requirement 
for JAK2 in signaling from two activated βc mutants (FIΔ and V449E) which display a 
differential requirement for GMRα.22 Parental FDB1 cells and cell populations with 
stable expression of FIΔ and V449E mutants were withdrawn from growth factor for 16h 
and lysates were prepared. As a control for signaling pathway activation, cell populations 
were also treated for 5 min with mIL-3 or mGM-CSF. Western immunoblot analysis was 
used to determine the phosphorylation status of JAK2 and its downstream effector 
STAT5A/B (Figure 1A). As predicted, we observed JAK2 and STAT5A/B 
phosphorylation in all FDB1 cell populations responding to IL-3 stimulation. While we 
observed robust constitutive JAK2 phosphorylation in FDB1 cells expressing the 
activated V449E mutation, FDB1 cells expressing FIΔ did not display constitutively 
activated JAK2 or STAT5A/B (Figure 1A). We observed negligible constitutive 
phosphorylation of ERK1/2 in FDB1 FIΔ cells compared to the robust constitutive 
activation of ERK1/2 seen in FDB1 V449E cells (Figure 1A). Growth factor stimulation 
of FIΔ and V449E expressing cells often results in lower levels of tyrosine 
phosphorylation than in the GF-stimulated parental FDB1 cells. This maybe associated 
with the constitutive nature of signalling in these cells and a potential reduction in wild-
type receptor levels, or from a feedback pathway from the constitutive receptors that 
suppresses receptor responses. A more sensitive single cell phospho-profiling approach27 
was also used to detect STAT5A/B and ERK1/2 phosphorylation (Figure 1B). Consistent 
with western immunoblot analyses, these results confirmed that FIΔ signals 
independently of STAT5 and ERK1/2 in the absence of growth factor, and that V449E 
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activates both STAT5 and ERK1/2, despite its lack of requirement for GMRα (Figure 
1B).    
 
To further assess the requirement for JAK2 and ERK signaling in the cellular response to 
the βc mutants, we assessed viability of FDB1 cell populations treated for 24hrs with JAK 
inhibitors, AG490 and JAK2 Inhibitor II (J2InhII), and the MEK inhibitors, U0126 and 
PD98059 (Figure 1C).  A 24 hour time point for viability was chosen as parental FDB1 
cells die by 24 hours post growth factor withdrawal and all functional attributes of the 
cells at this time are presumed to be attributed the signaling of the activated receptors. 
FDB1 FIΔ cells undergo differentiation so effects at later time points may not be 
inhibitor-specific and may represent changes that occur as the cells differentiate. Murine 
IL-3 stimulation following GF starvation was used as a control in these experiments as 
the transient activation of endogenous murine receptors provides an indication of 
starvation efficiency. Treatment of FDB1 cell populations with 25µM AG490 and 25µM 
J2InhII resulted in a significant reduction in the levels of phospho-JAK2 and phospho-
STAT5A/B as detected by immunoblot analysis (Supplementary Figure 1A). An average 
of 30% and 48% reduction in the viability of FDB1 V449E cells was observed following 
AG490 and J2InhII treatment respectively (Figure 1C). In contrast, the JAK inhibitors 
had a lesser effect on the viability of FDB1 FIΔ cells following growth factor withdrawal, 
consistent with the generation of JAK2-independent signals by the FIΔ mutant receptor 
(Figure 1C).   
 
MEK kinases lie upstream of MAPK and treatment with MEK inhibitors results in 
inhibition of ERK1/2 activity. We tested the effect of two MEK inhibitors, PD98059 and 
U0126 on the viability of all FDB1 cell populations.  No effect was seen on the viability 
of parental or FDB1 FIΔ cells following growth factor-withdrawal and treatment with 
50µΜ PD98059 or 25µM U0126, consistent with the phosphorylation status of ERK1/2 
in these cells (Figure 1D).  Conversely, FDB1 V449E cells, showed a marked decrease in 
cell viability to approximately 40% by 24 hours following MEK inhibitor treatment 
(Figure 1D). Treatment of FDB1 cells with U0126 and PD98059 resulted in a significant 
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reduction in the levels of phospho-ERK1/2 as detected by immunoblot analysis 
(Supplementary Figure 1B). These inhibitor studies suggest a major contribution of both 
JAK2/STAT5 and ERK1/2 pathways in promoting survival of cells expressing the 
V449E mutant consistent with previous reports implicating these pathways in cell 
survival and proliferation.28  
 
Differential activation of p85/Akt and IκKβ/NFκB Pathways by the activated βc  mutants 
We next assessed activation of Akt, a downstream effector of p85, and IκB, a signaling 
molecule downstream of IκKβ that de-represses the NFκB survival pathway, in response 
to FIΔ and V449E expression in FDB1 cells.  Lysates from FDB1 cell populations, 
starved and stimulated with mIL-3 or mGM-CSF, were immunoblotted with phospho-Akt 
and phospho-IκKβ antibodies to measure activation of these pathways.  Interestingly, FIΔ 
cells displayed high levels of constitutive Akt and IκB phosphorylation in contrast to 
V449E expressing cells which showed minimal constitutive phosphorylation of either 
Akt or IκB (Figure 2A). Cells expressing the V449E mutant showed little 
phosphorylation of either Akt or IκB when stimulated with mIL-3 or mGM-CSF, 
compared to parental or FDB1 FIΔ cells (Figure 2A).  FDB1 cells expressing FIΔ were 
sensitive to two PI3K inhibitors, showing a significant decrease in cell viability over a 24 
hour period to 28% with 25µM LY294002 and 42% with 0.5µM Wortmannin (Figure 
2B). Wortmannin and LY294002 had less significant effect on the viability of FDB1 
V449E cells consistent with the lack of constitutive Akt phosphorylation by this mutant 
and with the presence of an alternative survival signal mediated by JAK2/STAT5 and 
ERK1/2 pathways.  All cells cultured in IL-3 maintained good viability irrespective of 
inhibitor treatment, emphasising the redundancy of the multiple pathways activated by 
IL-3 (Figure 2B). All cell populations treated with PI3K inhibitors showed a significant 
reduction in the levels of phospho-Akt as detected by immunoblot analysis 
(Supplementary Figure 1C). 
 
Role of GMRα and SFKs in FIΔ signaling 
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Given the strict requirement of the FIΔ mutant for GMRα26 and the lack of JAK2 
activation by this mutant we next wished to identify molecules associated with GMRα 
that may contribute to constitutive activation of this mutant. The regulatory subunit of 
PI3K, p85, has been previously shown to associate with the GMRα subunit cytoplasmic 
domain, an interaction that is dependent upon the SH3 domain of p85 binding to the 
membrane-proximal proline-rich sequence in the short cytoplasmic domain of the 
GMRα.19  Additionally, IκKβ, has been shown to directly interact with the GMRα in a 
yeast-2-hybrid screen.20 With a view to identifying the signaling components that are 
present in the GMRα:FIΔ complex we used several approaches to identify proteins 
binding to the GMRα-subunit cytoplasmic domain. Immunoprecipitation was used to 
confirm previously reported associations of p85 and IκKβ with GMRα.19,20 Co-
immunoprecipitation of GMRα with p85 and IκKβ was readily observed in HEK293T 
cells transiently expressing human GMRα consistent with published reports (Figure 3A 
and B). Using a form of GMRα in which the two outer prolines in the PPVP motif are 
mutated to alanine (APVA), we show that the interaction of p85 with GMRα is 
dependent on the intact SBP motif (Figure 3C). Association of IκKβ with GMRα is 
consistent with activation of this pathway by FIΔ and with several reports of NF-κB 
activation by GM-CSF and IL-3 playing an important role in modulating survival in 
myeloid cells.20,29  We postulated that the interaction of GMRα with IκKβ is unlikely to 
involve the SBP motif as the sequence/structures of IκKβ do not have known proline-
interaction domains (SH3 or WW domains). Consistent with this, we show that IκKβ can 
still interact with the GMRα-APVA mutant (Figure 3D).  
 
In addition to confirming previously reported interactions with GMRα, we aimed to 
identify novel interactions with GMRα (Figure 4A). As the SBP motif of GMRα17 
includes an excellent match to the SH3 binding consensus we used a direct binding assay 
to identify interacting proteins with SH3 domains. Incubation of filters containing 
immobilised, recombinant SH3 domains (150 proteins, Panomics), with a fluorescently 
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labelled peptide corresponding to the proline-rich core of the human GMRα SBP motif, 
identified binding to the SH3 domains of Lyn, Src, CrkD2, and Nck2 (data not shown).  
Lyn and Src have known roles in cytokine receptor signalling and were thus analysed 
further. Co-immunoprecipitation studies confirmed the interaction of Lyn with GMRα in 
HEK293T cells (Figure 4A) and this interaction was lost with the GMRα-APVA mutant 
(Figure 4B). Similarly, we show co-immunoprecipitation of Src with GMRα, and 
reduced binding to GMRα-APVA (Figure 4C). GST pull-down experiments were also 
used to demonstrated binding of Lyn and Src with GMRα. GST fusion proteins of Lyn 
and Src SH3 domains were generated and used as “bait” to capture GMRα transiently 
over-expressed in HEK293T cells. Interactions were confirmed for both Lyn SH3 and Src 
SH3 domains with GMRα, and were abrogated with GMRα-APVA (Supplementary 
Figure 2). Additionally, the use of a fluorescence polarisation assay30 with a 
fluorescently-labelled human GMRα-SBP peptide demonstrated selective and direct 
binding of the peptide to GST-Lyn SH3 and GST-Src SH3 domain fusion proteins with a 
weaker interaction (not significant) observed for p85-SH3 (Figure 4D).  Given that JAK2 
and p85 have been shown to physically associate with Lyn,31 it is possible that p85 binds 
to GMRα through Lyn. Using several binding assays we were unable to detect an 
interaction between JAK2 with GMRα (data not shown), also reported elsewhere.12,32  
 
The direct association of Lyn and Src with GMRα suggests the possibility that the SFKs 
may play an important role in the response to GM-CSF and be particularly important for 
the FIΔ activated mutant. We next used SFK-selective inhibitors to test whether the SFKs 
are selectively contributing to FIΔ-mediated survival and differentiation of FDB1 cells. 
We utilized two independent SFK inhibitors, 25µM PP1 and 5µM SU6656, that reduce 
the activity of both Src and Lyn (Supplementary Figure 1D). Importantly, in the absence 
of growth factor FDB1 FIΔ cells showed sensitivity to SFK inhibitors with a clear 
reduction in viability (reduced to ~40% with both inhibitors; Figure 4E). In order to 
further assess the role of Lyn specifically we used a Lyn-binding, peptide inhibitor which 
comprises a hβc sequence known to interact with Lyn, thus resulting in Lyn sequestration 
13 
and preventing its activation by GMR.33,34 Treatment of FDB1 FIΔ cells with the Lyn 
peptide inhibitor resulted in a significant reduction in viability at the two concentrations 
used (10µM and 25µM), and had no effect on FDB1-V449E cells (Figure 4F).  The 
observation that V449E-mediated survival is not affected by treatment with SFK or Lyn-
specific inhibitors suggests this pathway is not critical for signaling from this mutant. The 
inhibitors are presumably not acting via a direct or indirect affect on JAK2 activity as 
cells expressing hGMRα and hβc maintain robust JAK2 activation in the presence of IL-3 
and GM-CSF when treated with SFK inhibitor (data not shown). Additionally, treatment 
of the FDB1 FIΔ cells with the SFK inhibitors did not affect IκB or Akt phosphorylation 
(Supplementary Figure 1D). The increased sensitivity of FDB1 FIΔ cells to SFK 
inhibition and the selective requirement for GMRα, together with the reduced sensitivity 
to JAK inhibition and the lack of JAK/STAT activation are consistent with an important 
signaling role for the SFKs in the FIΔ-mediated response. This mutant thus provides a 
tool for dissecting the roles of SFKs in GM-CSF receptor signaling.  
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Discussion 
 
GM-CSF has recently been demonstrated to induce a unique receptor subunit 
configuration involving formation of a dodecameric complex, which results in JAK2 
dimerisation and activation of JAK/STAT, ERK1/ERK2, PI3K/Akt, IκB/NFκB 
downstream pathways.12  In normal cells these pathways cooperate to induce growth, 
survival and/or differentiation responses that are cell type and context dependent. In 
leukemic cells these GM-CSF-induced pathways make an important contribution to 
proliferation and survival.10 In particular, constitutive serine phosphorylation of GM-CSF 
receptor has been reported in primary AML cells, associated with an unknown 
mechanism of receptor activation.35  
 
To dissect the relative contribution of GMRα and βc to pathway activation, and the role 
of each of these pathways in particular cell responses, we have used βc activated mutants 
which differentially require GMRα, and that activate non-redundant subsets of pathways 
and responses allowing association of signaling with alternative receptor configurations 
and cellular outcomes. This has provided evidence for JAK2-independent and SFK-
dependent signals associated with GMRα. Taken together with evidence of association of 
GMRα with the SFKs Lyn and Src this suggests a novel contribution of GMRα to 
responses downstream of GMR.  
 
A comprehensive biochemical analysis revealed non-overlapping signaling profiles of the 
βc mutants FIΔ and V449E. In the FIΔ mutant the survival response is mediated 
predominantly by the PI3K/Akt and IκKβ/NFκB pathways which are activated in the 
absence of detectable JAK2 activation. Whilst highly sensitive to PI3K inhibitors, the FIΔ 
mutant displayed relative resistance to two JAK inhibitors in keeping with the limited 
requirement for activation of JAK2. We and others have shown recruitment of the p85 
regulatory subunit of PI3K to the GMRα and this may facilitate activation of PI3K/Akt 
signaling in FIΔ in the absence of JAK2 activity.19 In contrast to the FIΔ mutant, 
signaling from V449E was associated with robust activation of JAK2/STAT5 and 
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ERK1/2, high relative sensitivity to MEK inhibitors, and a lack of detectable Akt or IκB 
phosphorylation. The lack of Akt activation by this mutant, which we have proposed 
previously to be associated with ligand-independent dimerisation (Figure 2A),26 is 
consistent with the observation that PI3K/Akt activity is not seen in BA/F3 cells 
expressing a βc/JAK2 chimera36 and suggests that JAK2 activation is not sufficient for 
activation of the PI3K/Akt pathway.  
 
A major question from these finding relates to the nature of the primary signaling event 
associated with the FIΔ mutant. JAK-independent signaling is known to contribute to 
important outcomes from CRs, including βc.37 JAK2-independent signaling is also 
consistent with our previous analysis of serial truncations of the FIΔ mutant, which 
indicate that the primary signal is associated with a region distal to the Box 1 motif 
responsible for JAK2 association.32 Given the strict requirement of the FIΔ mutant for 
GMRα we explored the protein interactions with the GMRα cytoplasmic domain. We 
have confirmed here association of GMRα with the p85 regulatory subunit of PI3 kinase, 
and with IκKβ, as reported previously.19,20  The finding that Src and Lyn associate with 
GMRα via the critical proline-rich SBP motif strongly implicates the SFKs as playing a 
key role in signaling from the FIΔ complex. This association of GMRα with Src and Lyn 
was demonstrated using both direct (GST pulldown and fluorescence polarization) and 
indirect (co-immunoprecipitation) methods and the role of the SBP motif was confirmed 
by site directed mutagenesis of the prolines in the SBP motif.  The association of Lyn and 
Src with the α-subunit via the SBP motif is consistent with studies demonstrating an 
important role for SFKs in receptor-mediated responses in the myeloid lineage. Members 
of the SFK family have been linked to activation of cellular signaling in response to GM-
CSF (Reviewed in 38); Lyn in particular is activated by IL-3, IL-5 or GM-CSF,  and can 
phosphorylate tyrosine residues in hβc in vitro.34  
 
Lyn in particular, may be critical in the JAK2-independent signaling from GMR. The FIΔ 
mutant displayed a selective sensitivity to a Lyn inhibitory peptide, consistent with Lyn 
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being a key initiator of signaling from the FIΔ mutant. The Lyn inhibitory peptide in 
particular, may be acting by inhibiting SFK associated with βc, however the selective 
sensitivity of the FIΔ mutant to this peptide together with the high relative sensitivity to 
the SFK inhibitors clearly demonstrates the differential requirement for SFKs in 
FIΔ signaling. In contrast, the resistance that V449E displays to treatment with SFK 
inhibitors, including the Lyn inhibitory peptide, indicates that it may generate additional 
or alternative SFK-independent survival signals (probably JAK2 mediated). These are 
primarily mediated via the MAPK pathway as treatment with MEK inhibitors 
dramatically and selectively affects the survival of V449E-expressing FDB1 cells. In the 
FDB1 system IL-3 survival responses are also relatively resistant to SFK inhibitor 
treatment and we propose that both JAK- and SFK-dependent survival pathways are 
being activated by the wild-type ligand-induced receptor complexes, with extensive 
redundancy. In vivo studies suggest that JAK2-independent signaling from hβc will 
support only limited responses; while myeloid progenitors from the fetal liver of JAK2-
deficient mice show a lack of growth responsiveness to IL-3 and GM-CSF,36,40 survival 
responses of JAK2 knockout progenitors in response to these growth factors have not 
been studied in detail.   
 
These signaling properties of the two activated mutants are consistent with the two 
classes of mutant representing alternative receptor complexes as proposed previously,26 
These complexes deliver at least some of the proliferative, survival, self-renewal and 
differentiative signals activated by a mature GM-CSF receptor complex. In Figure 5 we 
summarise the properties of these mutants in the context of the unique GM-CSF 
dodecameric receptor structure.12 We propose that the FIΔ and V449E activated receptor 
complexes initiate non-overlapping signaling events resulting in activation of 
complementary pathways and non-redundant signaling. These alternative events may be 
initiated within the WT dodecamer complex via the αββα tetramer structure or the αβ 
heterodimers (Figure 5). This would predict that the αββα complex signals 
predominantly through activated JAK2. It also raises the possibility that pathways 
downstream of JAK2 (eg Shc initiated activation of SHIP) suppress Akt activation from 
17 
the αβ heterodimer12 suggesting a mechanism for cross-regulation of signaling within the 
dodecamer. The tetrameric structure predicted for the FIΔ mutant would preclude JAK2 
activation and thus signaling would occur predominantly via JAK-independent 
mechanisms, including those signals generated from the GMRα. Whether these 
alternative complexes shown in Figure 5 represent intermediates in formation of the 
mature GM-complex is not clear. The recent demonstration that low concentrations of 
GM-CSF induce a limited signalling response10,41 is consistent with a role for these 
alternative receptor configurations in certain contexts, including leukemic cell survival. 
Lyn is frequently activated in leukemic blasts from AML patients42 and in CML blast 
crisis;43 and these studies raise the possibility that this is related to aberrant GM-CSF or 
IL-3 receptor signaling. We suggest that further studies with these mutants will facilitate 
the identification of the role of SFKs in GM-CSF responses and may shed light on the 
mechanisms associated with aberrant GM-CSF and Lyn activation in leukaemia .  
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Figure Legends 
 
Figure 1. The hβc FIΔ  mutant generates JAK2- and ERK1/2-independent signals. 
(A) FDB1 cell populations were cultured without growth factor (NF) for 16hr and then 
stimulated with mIL-3 or mGM-CSF for 5 min.  Whole cell lysates (WCL) were 
subjected to western blot analysis with the indicated antibodies. (B) FDB1 cells were 
cultured in the absence of growth factor (NF), mIL-3 or mGM-CSF, then fixed, 
permeabilised and stained with the indicated primary antibodies (open histograms) or 
isotype matched control (grey histograms). (C) FDB1 cells were cultured with DMSO, 
JAK2 inhibitor II (J2InhII), or AG490. After 24hr, viability of cells was measured by 7-
AAD staining and flow cytometry. (D) FDB1 cells expressing receptor mutants were 
cultured with DMSO, U0126, or PD98059 (PD). Viability was measured at 24hr by 
7AAD staining and flow cytometry. Error bars represent standard error of the mean 
where n=3, statistical significance was calculated using a student t-test, *p<0.05 
**p<0.001. 
 
Figure 2. The hβc FIΔ  mutant signals through Akt and NFκB pathways. 
(A) FDB1 cells were cultured without growth factor (NF) for 16hr and then stimulated 
with mIL-3 or mGM-CSF for 5 min. Whole cell lysates were subjected to western blot 
analysis with the indicated antibodies. (B) FDB1 cells were cultured with DMSO, 
LY294002 (LY), or Wortmannin (Wort). After 24hr cell viability was measured by 7-
AAD staining and flow cytometry. Error bars represent standard error of the mean where 
n=2, statistical significance was calculated using a student t-test, *p<0.05 **p<0.001. 
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Figure 3. IκKβ  and p85 interact with hGMRα . 
(A) Flow cytometric analysis to detect hGMRα and hGMRα-APVA following 
transfection of HEK293T cells. hGMRα was detected with 4H1 antibody (open 
histograms). An isotype-matched control is shown for comparison (grey histograms). (B) 
hGMRα, p85 and IκB detected in whole cell lysates (WCL) from HEK293T cells 
expressing hGMRα, and in 4H1 immunoprecipitates (4H1 IP) and minus antibody (-Ab) 
or IgG1 (IgG1) control immunoprecipitates. (C) hGMRα and p85 detected in WCL from 
HEK293T cells expressing hGMRα or hGMRα-APVA, and in 4H1 immunoprecipitates 
(4H1 IP) of the same cells. (D) hGMRα and IκB detected in WCL from HEK293T cells 
expressing hGMRα or hGMRα-APVA, and in 4H1 (4H1 IP) and minus antibody (-Ab) 
or IgG1 (IgG1) control immunoprecipitates of the same cells.    
 
Figure 4. Association of Lyn and Src SH3 domains with hGMRα . 
(A) hGMRα and Lyn detected in whole cell lysates (WCL) from HEK293T cells 
expressing hGMRα, and 4H1 immunoprecipitates (4H1 IP). (B) hGMRα and Lyn 
detected in WCL from HEK293T cells expressing hGMRα or hGMRα-APVA, and in 
4H1 (4H1 IP) and IgG1 (IgG1) control immunoprecipitates of the same cells. (C) 
hGMRα and Src detected in WCL from HEK293T cells expressing hGMRα or hGMRα-
APVA, and in 4H1 (4H1 IP) and IgG1 (IgG1) control immunoprecipitates of the same 
cells. (D)  Fluorescence polarisation analysis of a fluorescein conjugated mGMRα 
23 
peptide alone, with GST, or with p85, Lyn and Src SH3 domain GST fusions proteins. 
The change in millipolarization (Δmp) is given, where emissions of the mGMRα peptide 
alone have been subtracted from the other samples. (E) Trypan blue viability of FDB1 
cells expressing receptor mutants after culture with DMSO, 0.5µM SU6656, or 25µM 
PP1 for 24hrs. (F) Trypan blue viability of FDB1 cells expressing receptor mutants after 
culture with DMSO, 10µM and 25µM Lyn peptide inhibitor (LI) for 24hrs. Error bars 
represent standard error of the mean where n=2, statistical significance was calculated 
using a student t-test, *p<0.05 **p<0.001. 
 
Figure 5. Model for assembly and activation of hβc mutants FIΔ  and V449E. 
The high affinity complex of the GM-CSF receptor (GMR) is a dodecamer structure 
(centre) comprising two ligand bound hexamers. The central structure in the dodecamer 
complex enables JAK2 transphosphorylation and activation of STAT5- and Shc-mediated 
pathways. Proposed signaling through GMRα occurs in αβ heterodimers (outer structures 
in the dodecamer complex) which initiate activation of Akt and NFκB pathways. Also 
indicated is a possible negative feedback mechanism whereby activation of SHIP 
downstream of JAK2 may inhibit GMRα−induced Akt activation. The proposed V449E 
structure is represented as a βc tetramer which does not require GMRα and initiates a 
subset of the signals generated by the dodecameric GMR complex. V449E activated 
pathways are confined to those downstream of JAK2 and receptor tyrosine 
phosphorylation, and support survival and proliferation in the FDB1 cells. The proposed 
FIΔ structure comprises an αβ tetramer which precludes JAK2 transphosphorylation. 
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This complex generates signals predominantly through GMRα and results in activation of 
Akt and NFκB pathways, supporting FDB1 survival and differentiation.  
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